What is Dostarlimab, a so -called medicine that works for cancer patients? Everything you must know about this cancer medicine
According to the World Health Organization, cancer is the biggest cause of mortality across the world. It accounts for almost 10 million deaths in 2020 that is nearly one death ratio in every six deaths (as per WHO).
A modest clinical trial conducted in Memorial Sloan Kettering Cancer Center in Manhattan, United States showed 100 percent eradication of malignant disease in cancer patients for the first time in history. Despite the fact that the experiment was conducted on a modest scale, it has aroused optimism that the globe would soon be free of the deadly cancer sickness.
According to the World Health Organization, cancer is the biggest cause of mortality among all diseases worldwide as it accounts for 1 death in every six cases. More categorized numbers are- Breast cancer (2.26 million cases), lung cancer (2.21 million cases), colon and rectum cancer (1.93 million cases), and prostate cancer (1.93 million cases) will be the most common malignancies in 2020. (1.41 million cases).
Here is what you might to know about the cancer research trail:
According to the New York Times, the experiment comprised 18 cancer patients who took a medicine named ‘Dostarlimab’ for about six months, and by the end of it, every single one of them had gotten rid of their tumours.
According to the New York Times, the 18 patients had already received cancer treatments such as chemotherapy, radiotherapy, and invasive surgery. According to reports, the patients went through the US trial anticipating to have to go through more surgeries in the next step. However, no more treatment was required.
Experts say the medicine ‘Dostarlimab’ has laboratory-made molecules that behave as substitute antibodies in the human body. According to experts, cancer can’t be detected by just physical examination which indicates that medicine could be the potential cure. As per ANI, Dr. Luis Alberto Diaz Jr., doctor of Memorial Sloan Kettering Cancer Center, New York said “for the very first time in the history of cancer this has happened that potential results have been seen.”
During the trial, cancer patients were given doses of Dostarlimab every 3 weeks for a period of 6 months. Notably, all of the patients had cancer that was at the same stage and had not progressed to other organs.
The trial has been described as “shocking” and “unprecedented” by specialists. Dr. Andrea Cercek, an oncologist in Memorial Sloan Kettering Cancer Center, told about patients’ feelings when they learned they were cancer-free: According to the New York Times, an oncologist said, “There were a lot of happy tears in the patient’s eyes.”